RadNet (RDNT) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Apr, 2026Executive summary
The annual meeting is scheduled for June 2, 2026, with voting on director elections, auditor ratification, executive compensation, and an amendment to the Equity Incentive Plan.
Proxy materials are available online, and shareholders are encouraged to vote via internet, phone, or mail.
A quorum requires a majority of outstanding shares, with 78,271,515 shares issued and outstanding as of the record date.
Voting matters and shareholder proposals
Six directors are nominated for election to serve until the 2027 annual meeting.
Ratification of Ernst & Young LLP as independent auditor for 2026 is proposed.
Advisory vote on executive compensation (say-on-pay) is included, with 83% approval in 2025.
Approval sought for an amendment and restatement of the Equity Incentive Plan, increasing the share reserve by 3,000,000 shares and extending the plan to 2036.
Board of directors and corporate governance
The board consists of a mix of independent and employee directors, with a lead independent director and standing audit, compensation, and nominating/governance committees.
Directors attended all meetings except one, and the board supports director education and biannual self-assessment.
Majority voting and director resignation policies are in place for uncontested elections.
Stockholder engagement and communication channels are emphasized.
Latest events from RadNet
- $103M all-stock deal forms a global AI breast imaging leader, targeting $7M+ cost synergies.RDNT
M&A Announcement9 Jul 2026 - Record revenue and EBITDA growth, AI expansion, and acquisitions led to raised 2025 guidance.RDNT
Q3 20259 Jul 2026 - Record Q2 revenue and EBITDA, strong AI growth, and raised 2024 guidance amid cost pressures.RDNT
Q2 20248 Jul 2026 - Advanced imaging and digital health drive robust growth, with major AI and OEM partnerships announced.RDNT
Bank of America Securities 2024 Leveraged Finance Conference8 Jul 2026 - AI-powered imaging and outpatient expansion drive double-digit growth and industry leadership.RDNT
44th Annual J.P. Morgan Healthcare Conference8 Jul 2026 - Q1 revenue up 9.2%, guidance raised, and iCAD acquisition to expand AI breast health.RDNT
Q1 20258 Jul 2026 - Advanced imaging, AI, and acquisitions drive robust growth and margin expansion for 2026.RDNT
47th Annual Raymond James Institutional Investor Conference8 Jul 2026 - Record Q1 revenue and EBITDA growth, raised 2026 guidance, and accelerated AI adoption.RDNT
Q1 202618 May 2026 - Record revenue, major AI acquisition, and strong 2026 growth outlook highlight the quarter.RDNT
Q4 20253 May 2026